Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of pamufetinib in osteosarcoma after standard chemotherapy
jRCT2080225239Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteosarcoma (OS) comparing Pamufetinib with Placebo (2 arms). Started Jun 2020; status: completed.
02
Drugs
pamufetinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on jRCT2080225239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225239.